Exciting news from Bactana! We are proud to announce the Canadian Vet Health Product registration of Pawsni™ Metabolic Health, the world's first product derived from the probiotic F. prausnitzii. With over 50% of cats and dogs considered overweight or struggling from metabolic health issues, clinically supported supplements like Pawsni play a crucial role in their well-being. We extend our gratitude to our research team, investors, and supporters who have helped us reach this milestone. Visit www.pawsni.com to learn more or shop. 

Funding will support Bactana’s development of novel microbiome-related products to enhance feed efficiency while also improving the safety of food products derived from animals

Read More>

Farmington startup Bactana developing drugs to combat diabetes in pets, potentially humans > READ MORE

This award enables expansion of Bactana’s leading therapeutic drug candidate to advance treatments for prediabetes and T2 diabetes for companion animals and potentially humans.

READ MORE>

The agreement will provide pet owners in France with access to Bactana’s Pawsni™ Glucose Control, the world’s first product derived from the commensal bacteria Faecalibacterium prausnitzii.

READ MORE>

Bactana is getting closer to bringing its first product to market and finding new uses for its microbiome discovery platform. The firm’s core product initiative – FPS – is based on a naturally occurring collection of ‘pioneer gut colonizers’ selected from the Faecalibacterium prausnitzii bacteria species. In 2018, Bactana received its initial equity financing to develop novel probiotics for ruminants.

Read More> (Featured in Animal Pharm).